Ipam

Indapamide, Amlodipine Besilate and Perindopril Arginine, the active ingredients in Ipam, are a combination antihypertensive presented as an oral tablet for systemic use. The formulation lowers elevated blood pressure in adult patients with primary hypertension.

GNH USA supplies Ipam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU marketing authorisation standards and is distributed under strict quality‑assured conditions. It is available for bulk procurement and can be shipped to regulated markets following appropriate import documentation.

Ipam is a combination antihypertensive that acts on the renin‑angiotensin system, calcium channels and diuretic pathways to control high blood pressure.

- Essential hypertension: lowers blood pressure in patients with primary hypertension. - Stage 1 hypertension: helps achieve target blood pressure when monotherapy is insufficient. - Stage 2 hypertension: provides additive effect for patients requiring multiple mechanisms.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain often related to blood pressure changes. - Peripheral edema: swelling of ankles or feet due to fluid retention. - Cough: dry throat irritation, typical of ACE‑inhibitor activity.

Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips, tongue, potentially airway‑obstructing. - Severe hypotension: marked drop in blood pressure causing faintness or shock. - Electrolyte imbalance: abnormal sodium or potassium levels, may cause cardiac arrhythmia.

Before initiating therapy, consider the following precautions: - Blood pressure monitoring: regularly assess to ensure therapeutic targets are met. - Renal function: evaluate creatinine clearance, especially in patients with chronic kidney disease. - Electrolyte assessment: check serum sodium and potassium levels due to diuretic effect. - Hepatic impairment: use cautiously in severe liver disease as drug metabolism may be altered. - Elderly patients: start at lower doses and monitor for orthostatic hypotension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Ipam may interact with several other medicines.

Major Interactions (Avoid): - Concurrent ACE inhibitors or ARBs: risk of additive renal dysfunction and hyperkalaemia. - Potassium‑sparing diuretics: may cause dangerous hyperkalaemia. - NSAIDs: can blunt antihypertensive effect and impair renal function. - Lithium: increased lithium levels leading to toxicity. - Other antihypertensives: excessive blood pressure lowering.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase amlodipine concentrations. - CYP3A4 inducers (e.g., rifampicin): may reduce amlodipine effectiveness. - Other calcium‑channel blockers: additive vasodilatory effects. - Loop diuretics: heightened risk of electrolyte disturbances. - Antidiabetic agents: may enhance hypoglycaemic response.